The Potential Effect of the IDH1 Mutation and MGMT Gene Promoter Methylation on the Control of Glioblastoma-Associated Epilepsy in Patients Receiving Anti-Epileptic Agents and Chemotherapies

The Potential Effect of the IDH1 Mutation and MGMT Gene Promoter Methylation on the Control of Glioblastoma-Associated Epilepsy in Patients Receiving Anti-Epileptic Agents and Chemotherapies

Objectives:(a) The objective of the study was to assess the control of seizure in glioblastoma patients receiving anti-epileptic drugs and chemotherapies after total resection and its association with O-methylguanine-DNA methyltransferase (MGMT) promoter methylation and the isocitrate dehydrogenase...

Full description

Bibliographic Details
Main Authors:	Maher KURDI, Nadeem Shafique BUTT, Saleh BAEESA, Badrah ALGHAMDI, Yazid MAGHRABI, Anas BARDEESI, Rothaina SAEEDI, Fahad ALGHAMDI, Najla ALGHANMI, Mohammed BARI, Alaa SAMKARI, Ahmed LARY, Taghreed ALSINANI, Sahar HAKAMY
Format:	Article
Language:	English
Published:	Galenos Yayinevi 2021-09-01
Series:	Archives of Epilepsy
Subjects:	anti-epileptic drugs epilepsy glioblastoma idh1 mutation mgmt promotor methylation temozolomide
Online Access:	http://archepilepsy.org/archives/archive-detail/article-preview/the-potential-effect-of-the-dh1-mutation-and-mgmt-/54631

Similar Items

Clinical impact of IDH1 mutations and MGMT methylation in adult glioblastoma
by: Magda Sayed Mahmoud, et al.
Published: (2024-03-01)

Correlations of MGMT promoter methylation and IDH1 mutations with the clinical prognosis of malignant glioma patients
by: ZHANG Ning, MA Hui-hui, WANG Fan, LIANG Wei, WANG Yi-chun, WU Bing-shan, LI Qing-xin
Published: (2021-10-01)

Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells
by: Jonas Feldheim, et al.
Published: (2022-05-01)

The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation
by: Francesco Marchi, et al.
Published: (2020-01-01)

Glioblastoma and the significance of MGMT gene methylation
by: Payam Izadpanahi, et al.
Published: (2014-08-01)

Glioblastoma and the significance of MGMT gene methylation
by: Payam Izadpanahi, et al.
Published: (2014-08-01)

Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study
by: Mario Caccese, et al.
Published: (2022-05-01)

The relationship between IDH, P53 mutations, MGMT methylation with characteristics in high grade glioma patients
by: Duc Anh Tran, et al.
Published: (2022-07-01)

Age-Dependent Impact of Concomitant Radio-Chemotherapy and MGMT Promotor Methylation on PFS and OS in Patients with IDH Wild-Type Glioblastoma: The Real-Life Data
by: Aleksandrs Krigers, et al.
Published: (2022-12-01)

The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas
by: Matthew McCord, et al.
Published: (2020-02-01)

The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas
by: Arne Christians, et al.
Published: (2019-10-01)

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
by: Melguizo Consolación, et al.
Published: (2012-12-01)

Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients
by: Federico Cucchiara, et al.
Published: (2022-07-01)

Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation
by: Luca Napoleoni, et al.
Published: (2019-01-01)

A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide
by: Rui-Chao Chai, et al.
Published: (2019-09-01)

Isocitrate dehydrogenase 1 and 2 genes mutations and MGMT methylation in gliomas
by: D. V. Tabakov, et al.
Published: (2017-04-01)

Epigenetic modification and characterization of the MGMT promoter region using CRISPRoff in glioblastoma cells
by: Remi Weber, et al.
Published: (2024-01-01)

Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma
by: Xinyu Han, et al.
Published: (2023-10-01)

MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value
by: Henning Leske, et al.
Published: (2023-08-01)

A ”Clickable” Probe for Active MGMT in Glioblastoma Demonstrates Two Discrete Populations of MGMT
by: Sudhir Raghavan, et al.
Published: (2020-02-01)

Improved Pathologic Diagnosis—Forecasting the Future in Glioblastoma
by: David J. Pisapia, et al.
Published: (2017-12-01)

MGMT expression in pituitary corticotroph adenomas and its relationship to clinical, pathological, and ultrastructural parameters in patients with Cushing’s disease
by: Przemysław Witek, et al.
Published: (2021-01-01)

The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis
by: Huy Gia Vuong, et al.
Published: (2020-09-01)

Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study
by: Jie Chen, et al.
Published: (2022-11-01)

Prognosis of MGMT-Positive Gene in Patients with Brain Tumors of Grade III and Grade IV
by: Ishitaa Rajendra, et al.
Published: (2023-03-01)

Epidemiological distribution of primary central nervous system tumors in the Western Province of Saudi Arabia: a local registry from neuroscience-affiliated centers
by: Maher Kurdi, et al.
Published: (2021-05-01)

Diagnostic Discrepancies Between Intraoperative Frozen Section and Permanent Histopathological Diagnosis of Brain Tumors
by: Maher KURDI, et al.
Published: (2022-01-01)

Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated <i>MGMT</i>
by: María del Mar Álvarez-Torres, et al.
Published: (2021-10-01)

MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers
by: Monica Niger, et al.
Published: (2022-07-01)

Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results
by: Matthew McCord, et al.
Published: (2023-11-01)

Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma
by: Ke Wang, et al.
Published: (2017-12-01)

The Significance of <i>MGMT</i> Promoter Methylation Status in Diffuse Glioma
by: Nikola Jovanović, et al.
Published: (2022-10-01)

Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment
by: Julius July, et al.
Published: (2020-08-01)

Transcriptomic analysis identifies the neuropeptide cortistatin (CORT) as an inhibitor of temozolomide (TMZ) resistance by suppressing the NF-κB-MGMT signaling axis in human glioma
by: Zongze He, et al.
Published: (2024-05-01)

Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide
by: Konstantin R. Brawanski, et al.
Published: (2023-03-01)

Survival Outcomes and Prognostic Factors in Glioblastoma
by: Nicholas F. Brown, et al.
Published: (2022-06-01)

Identification of MGMT Downregulation Induced by miRNA in Glioblastoma and Possible Effect on Temozolomide Sensitivity
by: Andrea Cardia, et al.
Published: (2023-03-01)

Role of Evaluating MGMT Status and 1p36 Deletion in Radiosurgery-Induced Anaplastic Ependymoma That Rapidly and Completely Resolved by Temozolomide Alone: Case Report and Review of the Literature
by: Seiichiro Hirono, et al.
Published: (2015-01-01)

Combination chemoradiotherapy with temozolomide, vincristine, and interferon-β might improve outcomes regardless of O6-methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation status in newly glioblastoma
by: Kenichiro Asano, et al.
Published: (2021-07-01)

An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?
by: Milan Teraiya, et al.
Published: (2023-04-01)